The new formula features a quartet of active ingredients: 4% glycolic, 3% phytic, 2% salicylic, and 1% mandelic acids. By utilizing varying molecular weights, the pads aim to provide depth-targeted exfoliation across different layers of the skin. Dr. Suzan Obagi emphasized that the product is designed to simplify consistent, nightly exfoliation, which she identifies as a cornerstone of long-term skin health.
Clinical data shared by the company suggests measurable improvements over two months. After four weeks, 97% of participants reported smoother skin texture. By the eight-week mark, 90% noted improved smoothness, while 83% reported a reduction in breakouts and blemishes. Justin Giouzepis, Chief Marketing Officer at Obagi, noted that the expansion of the CLENZIderm M.D. franchise serves to bridge the gap between dermatologist-led treatments and consumer-accessible home care.

Comments (0)
No comments yet. Be the first!